The Oncologist, Vol. 9, Suppl 3, 1619,
June 3, 2004
© 2004 AlphaMed Press
The Role of ErbB Inhibitors in Trastuzumab Resistance
Kathy D. Miller
Indiana University School of Medicine, Indianapolis, Indiana, USA
Correspondence:
Kathy D. Miller, M.D., Indiana University School of Medicine, Indiana Cancer Pavilion, 535 Barnhill Drive, RT-473, Indianapolis, Indiana 46202, USA. Telephone: 317-274-0920; Fax: 317-274-3646; e-mail: kathmill{at}iupui.edu
The ErbB family of receptors and ligands is a complex, delicately balanced system involved in the growth and differentiation of normal human cells as well as neoplasms. Targeting this system with therapies that inhibit ErbB receptor activity in cancer patients has been somewhat successful, but resistance to ErbB inhibitor monotherapy is substantial. An understanding of the biology of ErbB receptor inhibitors is necessary to determine how best to utilize them in treatment regimens. Experimental evidence has provided valuable insights regarding mechanisms involved in resistance, and indicates that resistance can be reversed in some models. Ongoing studies in patients are evaluating whether agents that target both the epidermal growth factor (EGFR, ErbB-1) and ErbB-2 (HER-2) receptors can prevent or delay resistance in patients with metastatic breast cancer that overexpresses HER-2. With a better understanding of the biology of breast cancer, and with several novel ErbB receptor inhibitors in development, continued progress for improved patient outcomes is expected.
Key Words. Breast cancer • Resistance • Trastuzumab • Tyrosine kinase receptor
This article has been cited by other articles:

|
 |

|
 |
 
Y. Bian, M. Sun, M. Silver, K. K. L. Ho, M. A. Marchionni, A. O. Caggiano, J. R. Stone, I. Amende, T. G. Hampton, J. P. Morgan, et al.
Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins
Am J Physiol Heart Circ Physiol,
December 1, 2009;
297(6):
H1974 - H1983.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Seve, J. Mackey, S. Isaac, O. Tredan, P.-J. Souquet, M. Perol, R. Lai, A. Voloch, and C. Dumontet
Class III {beta}-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel
Mol. Cancer Ther.,
December 1, 2005;
4(12):
2001 - 2007.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Escuin, E. R. Kline, and P. Giannakakou
Both Microtubule-Stabilizing and Microtubule-Destabilizing Drugs Inhibit Hypoxia-Inducible Factor-1{alpha} Accumulation and Activity by Disrupting Microtubule Function
Cancer Res.,
October 1, 2005;
65(19):
9021 - 9028.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. R. Fantin, M. J. Berardi, H. Babbe, M. V. Michelman, C. M. Manning, and P. Leder
A Bifunctional Targeted Peptide that Blocks HER-2 Tyrosine Kinase and Disables Mitochondrial Function in HER-2-Positive Carcinoma Cells
Cancer Res.,
August 1, 2005;
65(15):
6891 - 6900.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. D. Pegram
Molecular Determinants of Trastuzumab Response/Resistance
Am. Assoc. Cancer Res. Educ. Book,
April 1, 2005;
2005(1):
155 - 159.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. D. Pegram, R. Pietras, A. Bajamonde, P. Klein, and G. Fyfe
Targeted Therapy: Wave of the Future
J. Clin. Oncol.,
March 10, 2005;
23(8):
1776 - 1781.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. W. Blayney, B. W. McGuire, S. E. Cruickshank, and D. H. Johnson
Increasing Chemotherapy Dose Density and Intensity: Phase I Trials in Non-Small Cell Lung Cancer and Non-Hodgkin's Lymphoma
Oncologist,
February 1, 2005;
10(2):
138 - 149.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by AlphaMed Press.
|
|